IART Quote, Financials, Valuation and Earnings

iRhythm Technologies, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -2.7%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.

Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 14.9%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $220.60 which suggests that it could grow by 20.52%. Given that iRhythm Technologies, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe iRhythm Technologies, Inc. is more attractive than Integra LifeSciences Holdings Corp..

Integra LifeSciences Holdings Corp. has a beta of 1.064, which suggesting that the stock is 6.408% more volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.099, suggesting its more volatile than the S&P 500 by 9.93%.

Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.

Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than iRhythm Technologies, Inc. quarterly revenues of $192.9M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.63x versus 8.28x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of 28.44%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat LeMaitre Vascular, Inc.'s return on equity of 15.17%.

Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 14.9%. On the other hand LeMaitre Vascular, Inc. has an analysts' consensus of $104.33 which suggests that it could grow by 22.86%. Given that LeMaitre Vascular, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe LeMaitre Vascular, Inc. is more attractive than Integra LifeSciences Holdings Corp..

Integra LifeSciences Holdings Corp. has a beta of 1.064, which suggesting that the stock is 6.408% more volatile than S&P 500. In comparison LeMaitre Vascular, Inc. has a beta of 0.676, suggesting its less volatile than the S&P 500 by 32.402%.

Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular, Inc. offers a yield of 0.94% to investors and pays a quarterly dividend of $0.20 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. LeMaitre Vascular, Inc. pays out 33.1% of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than LeMaitre Vascular, Inc. quarterly revenues of $61M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than LeMaitre Vascular, Inc.'s net income of $17.4M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while LeMaitre Vascular, Inc.'s PE ratio is 36.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.63x versus 8.20x for LeMaitre Vascular, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of 14.46%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Masimo Corp.'s return on equity of -19.18%.

Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 14.9%. On the other hand Masimo Corp. has an analysts' consensus of $183.13 which suggests that it could grow by 32.61%. Given that Masimo Corp. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Masimo Corp. is more attractive than Integra LifeSciences Holdings Corp..

Integra LifeSciences Holdings Corp. has a beta of 1.064, which suggesting that the stock is 6.408% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Masimo Corp. quarterly revenues of $371.5M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than Masimo Corp.'s net income of $53.7M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.63x versus 4.36x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -8.49%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.

Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 14.9%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $22.52 which suggests that it could grow by 13.02%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Tandem Diabetes Care, Inc..

Integra LifeSciences Holdings Corp. has a beta of 1.064, which suggesting that the stock is 6.408% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.685, suggesting its more volatile than the S&P 500 by 68.536%.

Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.63x versus 1.32x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.